2Korovesis S, Karvouni E, Giazitzoglou E, et al. Drug-eluting stents: immediate and long term results[J]. Hellenic J Car diol,2005, 46( 5): 3311-335.
3Gao RI., Xu B, Lu SZ,et al. Safety and efficacy of the CY PHER Select Sirolimus-eluting stent in the "Real World"- clinical and angiographie results from the China CYPHER Se lect registry[J].Int J Cardiol, 2008,125(3): 339-346.
4Cutlip DE, Windecker S, Mehran R, et al. Clinical end point in coronary stent trials: a case for standardized definitions [J].Circulation, 2007,]15(17):2344 2351.
5Takahashi S, Kaneda H, Tanaka S, et al. Late gngiographic stent thrombisis after sirolimus-eluting stent implantation [J]. Circ J,2007,71(2):226-228.
6Makino Y, Hosoda H, Shibata K, et al. Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy[J]. Hypertension, 2002,39 (3) :781-784.
7Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and la'te thrombofc risk[J]. J Am Coil Cardiol,2006,48 ( 1 ) :193-202.
8Ge J, Qian J, Wang X, et al. Effectiveness and safety of the sirolimus- eluting stents coated with bioabsorbable polymer coating in human coronary arteries[J]. Catheter Cardiovasc Interv, 2007,69(2): 198- 202.
9Han Y, Jing Q, Chen X,et al. Long-term clinical, angiogra phic, and intravascular ultrasound outcomes of biodegradable polymer coated sirolimus-eluting stents [J]. Catheter Cardiovasc Interv, 2008,72(2) :177- 183.
